TxCell to present its cellular immunotherapy developments at leading investor conferences

Regulatory News:

TxCell SA (Paris:TXCL) (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Stephane Boissel, CEO, TxCell and other senior management will either attend, present to, and/or meet investors at a number of leading forthcoming investor conferences.

These investor conferences include:

• 15^th Annual Biotech in Europe Forum, organized by Sachs Associates, Basel, Switzerland - September 29 – 30, 2015
• Société Générale Healthcare & Biotechnology Conference, Paris, France - November 5, 2015
• 3^rd Annual EU Advanced Therapies Investor Day organized by the Alliance for Regenerative Medicine, London, UK – November 12, 2015
• 3^rd European Healthcare Conference organized by Bryan Garnier, Paris, France - November 12 – 13, 2015
• Salon Actionaria, Paris, France - November 20 – 21, 2015
• The 19^th Oddo forum, organized by Oddo, Lyon, France - January 7 – 8, 2016
• JP Morgan 34^th Annual Healthcare Conference, San Francisco, US - January 11 – 15, 2016
• NobleCon12, the 12^th Annual Emerging Growth Investor Conference, organized by Noble Financial Capital Markets, Florida, US - January 19 – 20, 2016.

About TxCell: www.txcell.com

TxCell develops innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need. TxCell has created ASTrIA, a unique and proprietary product platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has initiated a phase IIb study of its lead product candidate, Ovasave® in refractory Crohn’s disease patients. This follows a phase I/IIa study in the same patient population reporting positive clinical efficacy and good tolerability. TxCell’s second product candidate, Col-Treg is for the treatment of autoimmune uveitis, a rare disease of the eye. Listed on the regulated market Euronext Paris, TxCell is a spin-off of Inserm (France’s National Institute for Health and Medical Research). TxCell has 66 employees based both at the headquarters located in the Sophia Antipolis technology park, Nice, France and at its manufacturing site in Besançon.

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150927005052/en/